Buried Science

Remedies › Turmeric › Depression · All remedies for depression

Turmeric and depression: what the evidence says

Based on the evidence, curcumin added to usual care modestly lowers depression scores in short randomized trials, though the trials are small and their quality is rated low.

4/5 Moderate

At least one well-run randomized trial in people on this outcome, with a positive result. How we score

We read 10 of the 22 systematic reviews PubMed lists (the others were about schizophrenia, multiple sclerosis and other conditions) and the 14 largest or most-cited trials: 24 of the 68 human-study records PubMed returned.

Pooled results agree on a small benefit. A 2021 meta-analysis of 10 trials (594 patients) found a standardized difference of −0.32 and three times the odds of responding, but rated the evidence low quality; a 2025 analysis of 15 trials in people with chronic illness found −0.65 with very high variation between trials.

A 2022 international guideline from biological-psychiatry and mood-disorder societies rated curcumin 'provisionally recommended' as an add-on for depression. A 2026 network analysis that kept only low-bias trials reported a curcumin effect for anxiety only, not depression.

Single trials are mixed. The largest, 227 obese adults with type 2 diabetes followed for 12 months in Thailand, and a 123-patient Australian trial found benefit; an Israeli add-on trial of 40 patients and a 30-person crossover found none. Nearly all trials lasted 4 to 12 weeks, and none shows curcumin can replace an antidepressant.

The evidence ladder higher rungs count for more
  1. Meta-analyses of trialspooled randomized trials6
  2. Human studiestrials and population studies12
  3. Case reportssingle people0
  4. Animal studiesmostly rodents181
  5. Lab studiescells, test tubes95

The studies in people, read one by one

ResultTypeWhat they didWhat they found
PositiveSystematic review / meta-analysis, 2021
594 people		Meta-analysis of 10 randomized trials, curcumin for depression or depressive symptoms
Measured: Depression scores, response, drop-out		Depression SMD −0.32 (95% CI −0.50 to −0.13); response OR 3.20; drop-outs no different. Evidence rated low quality. PubMed 33418373
PositiveSystematic review / meta-analysis, 2020
531 people		Meta-analysis of 10 studies, curcumin in depression (7 major depression, 2 depression with medical illness)
Measured: Depression and anxiety scores		Hedges g −0.75 (95% CI −1.11 to −0.39) for depression; authors warn the sample is small. PubMed 31423805
PositiveSystematic review / meta-analysis, 2017
377 people		Meta-analysis of 6 placebo-controlled trials, curcumin in depression
Measured: Hamilton depression score		Pooled SMD −0.344 (95% CI −0.558 to −0.129); trials lasted 4–8 weeks; too few trials to test publication bias. PubMed 28236605
PositiveSystematic review / meta-analysis, 2025
1,123 people		Meta-analysis of 15 randomized trials, curcumin for depression or anxiety in people with chronic diseases
Measured: Depressive and anxiety symptoms		Depression SMD −0.65 (95% CI −1.16 to −0.13) with very high heterogeneity (I² 93%); anxiety SMD −0.22. PubMed 40918536
PositiveSystematic review / meta-analysis, 2022International guideline (WFSBP and CANMAT taskforce) grading meta-analyses and trials of supplements
Measured: Strength of recommendation for unipolar depression		Curcumin rated "provisionally recommended" (++) for unipolar depression, mainly as an add-on within standard care. PubMed 35311615
MixedSystematic review / meta-analysis, 2025Network meta-analysis of 192 trials of 44 supplements for depression
Measured: Change in depressive symptoms		Curcumin added to antidepressants beat antidepressants alone (SMD 1.03, 95% CI 0.55–1.51); curcumin alone vs antidepressants was not significant (0.62, 95% CI −0.17 to 1.40). PubMed 40314175
MixedSystematic review / meta-analysis, 2026Network meta-analysis of 163 trials of supplements for major depression, with a low-bias-only re-analysis
Measured: Depression and anxiety scores		In the strict low-risk-of-bias analysis the abstract reports a curcumin effect only for anxiety (2 trials, 89 people, SMD −0.58), not for depression. PubMed 42680855
PositiveRandomized trial, 2024
227 people		Double-blind placebo-controlled trial, curcumin for 12 months, obese adults with type 2 diabetes (Thailand)
Measured: Depression severity (PHQ-9)		Depression scores improved more than placebo at 12 months (p = 0.000001), with higher serotonin and lower inflammatory markers. PubMed 39125295
PositiveRandomized trial, 2017
123 people		Double-blind placebo-controlled trial, curcumin extract 250 or 500 mg twice daily, or curcumin plus saffron, for 12 weeks, major depression (Australia)
Measured: Self-rated depression (IDS-SR30), anxiety		Active treatments combined beat placebo on depression (p = 0.031) and anxiety; no difference between doses or with added saffron. PubMed 27723543
PositiveRandomized trial, 2018
65 people		Double-blind placebo-controlled add-on trial, curcumin 500–1,500 mg/day for 12 weeks, major depression (Thailand)
Measured: MADRS depression score		Curcumin beat placebo at weeks 12 and 16; effect larger in men; no notable side effects. PubMed 29327213
PositiveRandomized trial, 2014
56 people		Double-blind placebo-controlled trial, curcumin 500 mg twice daily for 8 weeks, major depression (Australia)
Measured: Self-rated depression (IDS-SR30)		No difference in the first 4 weeks; from week 4 to 8 curcumin did better (p = 0.045). Authors call it partial support. PubMed 25046624
PositiveRandomized trial, 2015
108 people		Double-blind placebo-controlled add-on trial, curcumin 1,000 mg/day for 6 weeks with antidepressants, men with major depression (China)
Measured: Hamilton and MADRS depression scores		Greater reduction in depression scores than placebo, with changes in inflammatory markers, BDNF and cortisol. PubMed 26066335
PositiveRandomized trial, 2025
96 people		Double-blind placebo-controlled trial, curcumin 500 mg/day for 8 weeks, first-time mothers after birth (Iran)
Measured: Postnatal depression score (EPDS)		Depression 2.5 points lower than placebo (95% CI −3.3 to −1.7, p < 0.001). PubMed 40281561
PositiveRandomized trial, 2020
80 people		Double-blind placebo-controlled trial, nano-curcumin 80 mg/day for 8 weeks, diabetic nerve damage (Iran)
Measured: Depression score (DASS-21)		Depression score fell from 16.7 to 15.3 vs 17.5 to 17.3 with placebo (p = 0.02); a small change. PubMed 31788880
MixedRandomized trial, 2014
60 people		Randomized observer-masked trial, curcumin 1,000 mg vs fluoxetine vs both for 6 weeks, major depression (India)
Measured: Response rate (HAM-D17)		Response 62.5% with curcumin, 64.7% fluoxetine, 77.8% both (p = 0.58); no placebo group, so it cannot show curcumin beats nothing. PubMed 23832433
PositiveClinical trial, 2015
111 people		Open-label controlled trial, curcuminoids plus piperine added to antidepressants for 6 weeks (Iran)
Measured: HADS and BDI-II scores		Greater reductions in anxiety and depression scores than antidepressants alone (p < 0.001); not blinded, no placebo. PubMed 25091591
No effectRandomized trial, 2013
40 people		Double-blind placebo-controlled add-on pilot, curcumin 500 mg/day for 5 weeks with escitalopram or venlafaxine (Israel)
Measured: Hamilton, MADRS, CGI		No difference from placebo (authors call it a negative result), with a non-significant trend to faster relief. PubMed 23673908
No effectRandomized trial, 2015
30 people		Double-blind crossover trial, curcumin 1 g/day for 30 days, obese adults (Iran)
Measured: Beck anxiety and depression scores		Anxiety improved (p = 0.03) but depression scores did not (p = 0.7). PubMed 25776839
No effectRandomized trial, 2025
19 people		Open-label randomized pilot, escitalopram with or without tetrahydrocurcumin 200 mg/day for 29 days (a curcumin metabolite)
Measured: HAMD-17 depression score		No difference in total depression score; gastrointestinal symptoms improved (p = 0.025). PubMed 41432971

Where the sources agree, and where they don’t

2 of 5 kinds of source point toward a benefit, 0 toward no effect or harm, 2 are mixed, and 1 has no data yet. Agreement between independent kinds of evidence matters more than the number of papers in any one of them.

Kind of sourcePoints toDetail
Meta-analyses of trialsPositivesmall effect, low-quality evidence
Treatment guidelinePositiveprovisionally recommended as an add-on (2022)
Strict low-bias analysisMixedeffect reported for anxiety only (2026)
Unpublished trialNo dataMeru Health add-on trial, 60 people
Public reportsMixed9 mood reports: 2 helped, 4 mixed, 2 no effect, 1 unclear

Beyond Google: 14 findings about Turmeric from trial registries, FDA reports and patent offices that a normal search rarely shows. See them

What people report

We read public first-person posts and counted every outcome, good or bad. 3 reports about this condition, read on 2026-10-28; 0 mention side effects.

  • 1Helped
  • 1No effect
  • 0Got worse
  • 0Mixed
  • 1Too early

Why these counts prove nothing on their own: people who post are not a random sample, most take other treatments at the same time, and nobody checks the diagnosis. We show them because they tell researchers what to test next.

Read all 3 reports
  • Too early Switched from sertraline to curcumin; feels great but thinks the depressive episode ended naturally. Mental Health Forum, 2015-02 (One month of use; poster credits natural recovery.)
  • Helped Takes turmeric for arthritis pain and has noticed it helps their depression somewhat. HealthUnlocked, 2022 (Year inferred from "4 years ago".)
  • No effect Noticed better balance, but cannot say turmeric lifts their depression. HealthUnlocked, 2022 (Hormone treatment at the same time.)

Every other paper we found

PubMed returned 476 papers for this search on 2026-10-28. We read the human studies above ourselves. The rest are sorted by type automatically from PubMed's labels, which are sometimes wrong. We removed 22 papers that only share a word with this search.

Animal studies 181
  1. Evaluation of anti-depressant, anxiolytic, and cognitive improvement effects of nanocurcumin using social isolation model in male mice: Behavioral and histopathological evaluation. Eur J Pharmacol, 2026
  2. The solid dispersion of a novel curcumin analogue (CACN136) prepared using PVP/Mannitol composite carrier significantly improved oral bioavailability and depression-like behavior in mice. Int J Pharm, 2026
  3. A Curcumin-Loaded Liposomal Thermoresponsive In Situ Nasal Gel for Brain Targeted Antidepressant Therapy. ACS Appl Mater Interfaces, 2026
  4. Therapeutic Potential of Nanocurcumin in Mitigating Duloxetine-Induced Hepatic Damage: Biochemical and Histopathological Insights. J Biochem Mol Toxicol, 2026
  5. Tetrahydrocurcumin ameliorates depression-like behaviors in chronic restraint stress mice by modulating neuroinflammation and neurotrophic balance via the SIRT1/NF-κB pathway. Nan Fang Yi Ke Da Xue Xue Bao, 2026
  6. Curcumin modulates oxidative stress, cortical activity and corticosterone in mice exposed to chronic social stress in the spontaneous aggressiveness model. Sci Rep, 2026
  7. Curcumin Alleviates Methotrexate-Induced Neurobehavioral Deficits and Modulates the Redox-Inflammatory-Neurotrophic Axis in Mice. J Biochem Mol Toxicol, 2026
  8. Intranasal Delivery of Curcumin-Loaded Pure Drug Self-Assembled Lipid-Based Nanoparticles for Targeted Therapy of Depression. Int J Nanomedicine, 2026
  9. Antidepressant and Anxiolytic Effects of Intranasal Curcumin in Parkinson's Disease Model Rats: Inhibition of Neuroinflammation and Oxidative Stress. Chin J Integr Med, 2026
  10. Sex-dependent therapeutic effects of nano-curcumin on alzheimer's disease: enhanced cognitive and physiological restoration in female mice. Psychopharmacology (Berl), 2026
  11. Effect of encapsulated spice oleoresins on chronic unpredictable mild stress-induced depression and gut microbiome modulation in mice model. Nutr Neurosci, 2026
  12. Curcumin Ameliorates Depressive-like Behaviors by Modulating mGluR2/PGC-1α-Mediated Glutamatergic Homeostasis and Mitochondrial Function. Mol Neurobiol, 2025
  13. Monitoring of Cerebral ROS and Alleviating Depressive-like Phenotype with a Curcumin-Derived Theranostic Probe. ACS Chem Neurosci, 2025
  14. Curcumin ZnO and MgO Nanoparticles Confer Protective Effects Against Ketamine-Induced Bipolar Disorder in Mice: Role of Brain-Derived Neurotrophic Factor. Adv Biomed Res, 2025
  15. On Anxiolytic and Antidepressant Effects of Curcumin in Sepsis-Induced Post-Intensive Care Syndrome: Antioxidant and Anti-Inflammatory Effects. Neuropsychobiology, 2025
  16. p53 promote oxidative stress, neuroinflammation and behavioral disorders via DDIT4-NF-κB signaling pathway. Redox Biol, 2025
  17. Protective Effects of Curcuma longa L. on Corticosterone-Induced Neurotoxicity and Anti-Depression-Like Behavior: Involvement of NMDA and 5-HT7A Receptors. J Microbiol Biotechnol, 2025
  18. Nano-Curcumin Mitigates Doxorubicin-Induced Reproductive Toxicity via Antioxidant, Anti-Apoptosis, and SIRT1-Modulating Effects in Rat Model. Toxics, 2025
  19. Novel chlorine-containing curcumin analogue CAK06 promotes neuroprotection and rapid antidepressant through Nrf2-induced anti-inflammatory and antioxidant effects. Neurotherapeutics, 2025
  20. Potential therapeutic effects of curcumin, with or without L-DOPA, on motor and cognitive functions and hippocampal changes in rotenone-treated rats. Metab Brain Dis, 2025
  21. Inhaled turmerone can attenuate nicotine-induced degeneration of the aorta. Fitoterapia, 2025
  22. Evaluation of Nanocurcumin Effects on Depressive-Like Behaviors in Rats and Determination of Serum BDNF and Serotonin Levels. Brain Behav, 2025
  23. Co-delivery of curcumin-resveratrol-carnosic acid complex promotes neurogenesis and cognitive recovery in a rodent model of repeated mild traumatic brain injury. Biomed Pharmacother, 2025
  24. Anti-inflammatory activity of the combination Ardisia humilis Vahl. and Curcuma xanthorrhiza Roxb. extract on an osteoarthritis rat model. Arch Physiol Biochem, 2025
  25. Preliminary Investigation Into the Antidepressant Effects of a Novel Curcumin Analogue (CACN136) In Vitro and In Vivo. Mol Neurobiol, 2025
  26. Curcumin and exercise prevent depression via alleviating hippocampus injury and improve depressive-like behaviors in chronically stressed depression rats. Res Pharm Sci, 2024
  27. Curcumin alleviates inflammatory effects of ketamine anesthesia in postnatal rats. Vet Res Forum, 2024
  28. A TNF-α inhibitor abolishes sepsis-induced cognitive impairment in mice by modulating acetylcholine and nitric oxide homeostasis, BDNF release, and neuroinflammation. Behav Brain Res, 2024
  29. Curcumin analogue NL04 inhibits spinal cord central sensitization in rats with bone cancer pain by inhibiting NLRP3 inflammasome activation and reducing IL-1β production. Eur J Pharmacol, 2024
  30. New curcumin-loaded nanocapsules as a therapeutic alternative in an amnesia model. Metab Brain Dis, 2024
  31. The role of turmeric and black pepper oil nanoemulsion in attenuating cytokine storm triggered by duck hepatitis A virus type I (DHAV-I)-induced infection in ducklings. Poult Sci, 2024
  32. J147 affects cognition and anxiety after surgery in Zucker rats. Physiol Behav, 2024
  33. Protective effects of curcumin on desipramine-induced islet β-cell damage via AKAP150/PKA/PP2B complex. Acta Pharmacol Sin, 2024
  34. Evaluation of the Therapeutic Effect of Curcumin-Conjugated Zinc Oxide Nanoparticles on Reserpine-Induced Depression in Wistar Rats. Biol Trace Elem Res, 2024
  35. Mechanistic insights into the anti-depressant effect of curcumin based on network pharmacology and experimental validation. Naunyn Schmiedebergs Arch Pharmacol, 2024
  36. Preparation and Evaluation of Curcumin Derivatives Nanoemulsion Based on Turmeric Extract and Its Antidepressant Effect. Int J Nanomedicine, 2023
  37. Turmeric Powder Counteracts Oxidative Stress and Reduces AFB1 Content in the Liver of Broilers Exposed to the EU Maximum Levels of the Mycotoxin. Toxins (Basel), 2023
  38. The role and mechanism of TGF-β1 in the antidepressant-like effects of tetrahydrocurcumin. Eur J Pharmacol, 2023
  39. J147 ameliorates sepsis-induced depressive-like behaviors in mice by attenuating neuroinflammation through regulating the TLR4/NF-κB signaling pathway. J Mol Histol, 2023
  40. The effect of curcumin on reserpine-induced depression-like behaviour in rats. Psychiatry Res Neuroimaging, 2023
  41. [Effect of processing with vinegar on efficacy of Curcuma longa in treatment of dysmenorrhea in rats with syndrome of liver depression and Qi stagnation]. Zhongguo Zhong Yao Za Zhi, 2023
  42. Mitochondrial dysfunction and type I interferon signaling induce anxiodepressive-like behaviors in mice with neuropathic pain. Exp Neurol, 2023
  43. Curcumin protects against doxorubicin induced oxidative stress by regulating the Keap1-Nrf2-ARE and autophagy signaling pathways. Psychopharmacology (Berl), 2023
  44. The effects of curcumin and sertraline on stress-induced changes in the stomach tissues of rats. Naunyn Schmiedebergs Arch Pharmacol, 2023
  45. Curcumin Ameliorates Neurobehavioral Deficits in Ambient Dusty Particulate Matter-Exposure Rats: The Role of Oxidative Stress. Neurochem Res, 2023
  46. Curcumin interferes with sepsis-induced cardiomyocyte apoptosis via TLR1 inhibition. Rev Port Cardiol, 2023
  47. Fluoxetine and Curcumin Prevent the Alterations in Locomotor and Exploratory Activities and Social Interaction Elicited by Immunoinflammatory Activation in Zebrafish: Involvement of BDNF and Proinflammatory Cytokines. ACS Chem Neurosci, 2023
  48. Modulatory role of dietary curcumin and resveratrol on growth performance, serum immunity responses, mucus enzymes activity, antioxidant capacity and serum and mucus biochemicals in the common carp, Cyprinus carpio exposed to abamectin. Fish Shellfish Immunol, 2022
  49. Synergistic effects of Lacticaseibacillus rhamnosus GG, glutamine, and curcumin on chronic unpredictable mild stress-induced depression in a mouse model. Benef Microbes, 2022
  50. [Curcumin alleviates the manganese-induced neurotoxicity by promoting autophagy in rat models of manganism]. Beijing Da Xue Xue Bao Yi Xue Ban, 2022
  51. Curcumin mitigates lipopolysaccharide-induced anxiety/depression-like behaviors, blood-brain barrier dysfunction and brain edema by decreasing cerebral oxidative stress in male rats. Neurosci Lett, 2022
  52. Coumarin derivatives as inhibitors of d-amino acid oxidase and monoamine oxidase. Bioorg Chem, 2022
  53. Effect of Curcumin in Experimental Pulmonary Tuberculosis: Antimycobacterial Activity in the Lungs and Anti-Inflammatory Effect in the Brain. Int J Mol Sci, 2022
  54. Curcumin ameliorated the mercuric chloride induced depression and anxiety in female mice offspring. Environ Res, 2022
  55. Compensatory depression of arterial pressure and reversal of ECG abnormalities by Annona muricata and Curcuma longa in hypertensive Wistar rats. J Complement Integr Med, 2022
  56. Curcumin Relieves Chronic Unpredictable Mild Stress-Induced Depression-Like Behavior through the PGC-1α/FNDC5/BDNF Pathway. Behav Neurol, 2021
  57. Prophylactic treatment of curcumin in a rat model of depression by attenuating hippocampal synaptic loss. Food Funct, 2021
  58. Neuroprotective effects of curcumin-loaded nanophytosome on ketamine-induced schizophrenia-like behaviors and oxidative damage in male mice. Neurosci Lett, 2021
  59. Therapeutic Potential of Curcumin in Reversing the Depression and Associated Pseudodementia via Modulating Stress Hormone, Hippocampal Neurotransmitters, and BDNF Levels in Rats. Neurochem Res, 2021
  60. Antidepressant effects of curcumin-coated iron oxide nanoparticles in a rat model of depression. Eur J Pharmacol, 2021
  61. Antidepressant-like effect of dehydrozingerone from Zingiber officinale by elevating monoamines in brain: in silico and in vivo studies. Pharmacol Rep, 2021
  62. Activation of monoaminergic system contributes to the antidepressant- and anxiolytic-like effects of J147. Behav Brain Res, 2021
  63. Enhanced neuroprotective and antidepressant activity of curcumin-loaded nanostructured lipid carriers in lipopolysaccharide-induced depression and anxiety rat model. Int J Pharm, 2021
  64. Curcumin mitigates neurotoxic and neurobehavioral changes of gentamicin and sodium salicylate in rats by adjusting oxidative stress and apoptosis. Life Sci, 2021
  65. Adaptogenic effects of curcumin on depression induced by moderate and unpredictable chronic stress in mice. Behav Brain Res, 2021
  66. Neuromodulatory effect of curcumin on catecholamine systems and inflammatory cytokines in ovariectomized female rats. Clin Exp Pharmacol Physiol, 2021
  67. Effect of fluoxetine on the testes of adult albino rats and the possible protective role of curcumin. Anat Sci Int, 2021
  68. Cardioprotective effect of pioglitazone and curcumin against diabetic cardiomyopathy in type 1 diabetes mellitus: impact on CaMKII/NF-κB/TGF-β1 and PPAR-γ signaling pathway. Naunyn Schmiedebergs Arch Pharmacol, 2021
  69. Curcumin Improves Chronic Pain Induced Depression Through Regulating Serum Metabolomics in a Rat Model of Trigeminal Neuralgia. J Pain Res, 2020
  70. Curcumin Attenuates Chronic Unpredictable Mild Stress-Induced Depressive-Like Behaviors via Restoring Changes in Oxidative Stress and the Activation of Nrf2 Signaling Pathway in Rats. Oxid Med Cell Longev, 2020
  71. Self-microemulsifying drug delivery system (SMEDDS) of curcumin attenuates depression in olfactory bulbectomized rats. Heliyon, 2020
  72. Long noncoding RNA GAS5 enhanced by curcumin relieves poststroke depression by targeting miR-10b/BDNF in rats. J Biol Regul Homeost Agents, 2020
  73. Curcumin-loaded lipid-core nanocapsules attenuates the immune challenge LPS-induced in rats: Neuroinflammatory and behavioral response in sickness behavior. J Neuroimmunol, 2020
  74. Effect of combination of curcumin and GLUT-1 AS-ODN on radiosensitivity of laryngeal carcinoma through regulating autophagy. Head Neck, 2020
  75. Curcumin amends Ca2+ dysregulation in microglia by suppressing the activation of P2X7 receptor. Mol Cell Biochem, 2020
  76. Anti-depressant effect of curcumin-loaded guanidine-chitosan thermo-sensitive hydrogel by nasal delivery. Pharm Dev Technol, 2020
  77. Curcumin-Loaded Nanocapsules Reverses the Depressant-Like Behavior and Oxidative Stress Induced by β-Amyloid in Mice. Neuroscience, 2019
  78. Curcumin lessens unpredictable chronic mild stress-induced depression and memory deficits by modulating oxidative stress and cholinergic activity. Pak J Pharm Sci, 2019
  79. Tetrahydrocurcumin protects against spinal cord injury and inhibits the oxidative stress response by regulating FOXO4 in model rats. Exp Ther Med, 2019
  80. Tetrahydrocurcumin Ameliorates Diabetic Cardiomyopathy by Attenuating High Glucose-Induced Oxidative Stress and Fibrosis via Activating the SIRT1 Pathway. Oxid Med Cell Longev, 2019
  81. Retraction: Suppression of Neuroinflammatory and Apoptotic Signaling Cascade by Curcumin Alone and in Combination with Piperine in Rat Model of Olfactory Bulbectomy Induced Depression. PLoS One, 2019
  82. Detection of Aflatoxin adducts as potential markers and the role of curcumin in alleviating AFB1-induced liver damage in chickens. Ecotoxicol Environ Saf, 2019
  83. Modulation of aflatoxin B1 cytotoxicity and aflatoxin M1 synthesis by natural antioxidants in a bovine mammary epithelial cell line. Toxicol In Vitro, 2019
  84. Involvement of the serotonergic system and neuroplasticity in the antidepressant effect of curcumin in ovariectomized rats: Comparison with oestradiol and fluoxetine. Phytother Res, 2019
  85. Curcumin relieves depressive-like behaviors via inhibition of the NLRP3 inflammasome and kynurenine pathway in rats suffering from chronic unpredictable mild stress. Int Immunopharmacol, 2019
  86. A diet enriched with curcumin promotes resilience to chronic social defeat stress. Neuropsychopharmacology, 2019
  87. Curcumin restores rotenone induced depressive-like symptoms in animal model of neurotoxicity: assessment by social interaction test and sucrose preference test. Metab Brain Dis, 2019
  88. Screening of active fractions from Curcuma Longa Radix isolated by HPLC and GC-MS for promotion of blood circulation and relief of pain. J Ethnopharmacol, 2019
  89. Electrocortical and Biochemical Evaluation of Antidepressant Efficacy of Formulated Nanocurcumin. Appl Biochem Biotechnol, 2019
  90. Neuroprotective Effects of Curcumin on IL-1β-Induced Neuronal Apoptosis and Depression-Like Behaviors Caused by Chronic Stress in Rats. Front Cell Neurosci, 2018
  91. Antidepressant-like effect of salidroside and curcumin on the immunoreactivity of rats subjected to a chronic mild stress model. Food Chem Toxicol, 2018
  92. Curcumin Protects Against Chronic Stress-induced Dysregulation of Neuroplasticity and Depression-like Behaviors via Suppressing IL-1β Pathway in Rats. Neuroscience, 2018
  93. Systemic Administration of Curcumin Affect Anxiety-Related Behaviors in a Rat Model of Posttraumatic Stress Disorder via Activation of Serotonergic Systems. Evid Based Complement Alternat Med, 2018
  94. Antidepressant-like effects of a novel curcumin derivative J147: Involvement of 5-HT1A receptor. Neuropharmacology, 2018
  95. Curcumin attenuates hepatic mitochondrial dysfunction through the maintenance of thiol pool, inhibition of mtDNA damage, and stimulation of the mitochondrial thioredoxin system in heat-stressed broilers. J Anim Sci, 2018
  96. The comprehensive electrophysiological study of curcuminoids on delayed-rectifier K+ currents in insulin-secreting cells. Eur J Pharmacol, 2018
  97. Stimulatory effects of curcumin and quercetin on posttranslational modifications of p53 during lung carcinogenesis. Hum Exp Toxicol, 2018
  98. Beneficial Effect of Chronic Treatment with Extracts from Rhodiola Rosea L. and Curcuma Longa L. on the Immunoreactivity of Animals Subjected to a Chronic Mild Stress Model. Folia Med (Plovdiv), 2017
  99. [Preliminary screening of biomarkers for curcumin's antidepressant effect based on metabonomics method]. Zhongguo Zhong Yao Za Zhi, 2017
  100. Oral Ingestion and Intraventricular Injection of Curcumin Attenuates the Effort-Related Effects of the VMAT-2 Inhibitor Tetrabenazine: Implications for Motivational Symptoms of Depression. J Nat Prod, 2017
  101. Targeting the Endocannabinoid/CB1 Receptor System For Treating Major Depression Through Antidepressant Activities of Curcumin and Dexanabinol-Loaded Solid Lipid Nanoparticles. Cell Physiol Biochem, 2017
  102. Curcumin reverses the depressive-like behavior and insulin resistance induced by chronic mild stress. Metab Brain Dis, 2017
  103. Effects of turmeric curcuminoids and metformin against central sensitivity to pain in mice. J Tradit Complement Med, 2017
  104. Investigation of the Anxiolytic and Antidepressant Effects of Curcumin, a Compound From Turmeric (Curcuma longa), in the Adult Male Sprague-Dawley Rat. Holist Nurs Pract, 2017
  105. Curcumin Alters Neural Plasticity and Viability of Intact Hippocampal Circuits and Attenuates Behavioral Despair and COX-2 Expression in Chronically Stressed Rats. Mediators Inflamm, 2017
  106. The protective effect of curcumin in Olfactory Ensheathing Cells exposed to hypoxia. Eur J Pharmacol, 2017
  107. Antidepressant effects of curcumin and HU-211 coencapsulated solid lipid nanoparticles against corticosterone-induced cellular and animal models of major depression. Int J Nanomedicine, 2016
  108. Polysorbate-80-coated, polymeric curcumin nanoparticles for in vivo anti-depressant activity across BBB and envisaged biomolecular mechanism of action through a proposed pharmacophore model. J Microencapsul, 2016
  109. Antioxidative and Neuroprotective Effects of Curcumin in an Alzheimer's Disease Rat Model Co-Treated with Intracerebroventricular Streptozotocin and Subcutaneous D-Galactose. J Alzheimers Dis, 2016
  110. Curcumin Rescues Diabetic Renal Fibrosis by Targeting Superoxide-Mediated Wnt Signaling Pathways. Am J Med Sci, 2016
  111. Analysis of anti-depressant potential of curcumin against depression induced male albino wistar rats. Brain Res, 2016
  112. Piperine Augments the Protective Effect of Curcumin Against Lipopolysaccharide-Induced Neurobehavioral and Neurochemical Deficits in Mice. Inflammation, 2016
  113. Co-administration of cisplatin and curcumin does not alter mood-associated behaviors. Bratisl Lek Listy, 2016
  114. Curcumin Ameliorates the Reduction Effect of PGE2 on Fibrillar β-Amyloid Peptide (1-42)-Induced Microglial Phagocytosis through the Inhibition of EP2-PKA Signaling in N9 Microglial Cells. PLoS One, 2016
  115. Neuropsychopharmacotherapeutic efficacy of curcumin in experimental paradigm of autism spectrum disorders. Life Sci, 2015
  116. Pretreatment with curcumin attenuates anxiety while strengthens memory performance after one short stress experience in male rats. Brain Res Bull, 2015
  117. A diet enriched with curcumin impairs newly acquired and reactivated fear memories. Neuropsychopharmacology, 2015
  118. The effect of curcumin on the brain-gut axis in rat model of irritable bowel syndrome: involvement of 5-HT-dependent signaling. Metab Brain Dis, 2015
  119. Regulation of biokinetics of (65)Zn by curcumin and zinc in experimentally induced colon carcinogenesis in rats. Cancer Biother Radiopharm, 2014
  120. The effects of curcumin on depressive-like behavior in mice after lipopolysaccharide administration. Behav Brain Res, 2014
  121. Effects of curcumin on learning and memory deficits, BDNF, and ERK protein expression in rats exposed to chronic unpredictable stress. Behav Brain Res, 2014
  122. The amelioration of phagocytic ability in microglial cells by curcumin through the inhibition of EMF-induced pro-inflammatory responses. J Neuroinflammation, 2014
  123. Amitriptyline up-regulates connexin43-gap junction in rat cultured cortical astrocytes via activation of the p38 and c-Fos/AP-1 signalling pathway. Br J Pharmacol, 2014
  124. Long-term curcumin treatment antagonizes masseter muscle alterations induced by chronic unpredictable mild stress in rats. Arch Oral Biol, 2014
  125. Effects of curcumin on chronic, unpredictable, mild, stress-induced depressive-like behaviour and structural plasticity in the lateral amygdala of rats. Int J Neuropsychopharmacol, 2014
  126. Neuroprotective and antioxidant effects of curcumin in a ketamine-induced model of mania in rats. Eur J Pharmacol, 2014
  127. Effect of curcumin on diabetic peripheral neuropathic pain: possible involvement of opioid system. Eur J Pharmacol, 2014
  128. Chronic curcumin treatment normalizes depression-like behaviors in mice with mononeuropathy: involvement of supraspinal serotonergic system and GABAA receptor. Psychopharmacology (Berl), 2014
  129. Neuroprotective and cognitive enhancing effects of a multi-targeted food intervention in an animal model of neurodegeneration and depression. Neuropharmacology, 2014
  130. Effects of curcumin on glucose metabolism in the brains of rats subjected to chronic unpredictable stress: a 18 F-FDG micro-PET study. BMC Complement Altern Med, 2013
  131. Antidepressant-like effects of curcumin in chronic mild stress of rats: involvement of its anti-inflammatory action. Prog Neuropsychopharmacol Biol Psychiatry, 2013
  132. Suppression of neuroinflammatory and apoptotic signaling cascade by curcumin alone and in combination with piperine in rat model of olfactory bulbectomy induced depression. PLoS One, 2013
  133. Further evaluation of the neuropharmacological determinants of the antidepressant-like effects of curcumin. CNS Neurol Disord Drug Targets, 2013
  134. Oily nanosuspension for long-acting intramuscular delivery of curcumin didecanoate prodrug: preparation, characterization and in vivo evaluation. Eur J Pharm Sci, 2013
  135. PAK1-deficiency/down-regulation reduces brood size, activates HSP16.2 gene and extends lifespan in Caenorhabditis elegans. Drug Discov Ther, 2013
  136. Ameliorative effect of Curcumin on seizure severity, depression like behavior, learning and memory deficit in post-pentylenetetrazole-kindled mice. Eur J Pharmacol, 2013
  137. Antidepressant-like effects of curcumin in WKY rat model of depression is associated with an increase in hippocampal BDNF. Behav Brain Res, 2013
  138. NMDA GluN2B receptors involved in the antidepressant effects of curcumin in the forced swim test. Prog Neuropsychopharmacol Biol Psychiatry, 2013
  139. Curcumin produces antidepressant effects via activating MAPK/ERK-dependent brain-derived neurotrophic factor expression in the amygdala of mice. Behav Brain Res, 2012
  140. Chronic treatment with curcumin enhances methamphetamine locomotor sensitization and cue-induced reinstatement of methamphetamine self-administration. Pharmacol Biochem Behav, 2012
  141. Protective effects of curcumin on amyloid-β-induced neuronal oxidative damage. Neurochem Res, 2012
  142. Anticancer activities against cholangiocarcinoma, toxicity and pharmacological activities of Thai medicinal plants in animal models. BMC Complement Altern Med, 2012
  143. Evaluation of antidepressant-like activity of novel water-soluble curcumin formulations and St. John's wort in behavioral paradigms of despair. Pharmacology, 2012
  144. The CB₁ receptor-mediated endocannabinoid signaling and NGF: the novel targets of curcumin. Neurochem Res, 2012
  145. Evaluation of antidepressant like activity of curcumin and its combination with fluoxetine and imipramine: an acute and chronic study. Acta Pol Pharm, 2011
  146. Curcumin inhibits glutamate release in nerve terminals from rat prefrontal cortex: possible relevance to its antidepressant mechanism. Prog Neuropsychopharmacol Biol Psychiatry, 2011
  147. Curcumin ameliorates reserpine-induced pain-depression dyad: behavioural, biochemical, neurochemical and molecular evidences. Psychoneuroendocrinology, 2011
  148. Gastroprotective and antidepressant effects of a new zinc(II)-curcumin complex in rodent models of gastric ulcer and depression induced by stresses. Pharmacol Biochem Behav, 2011
  149. Dual effects of curcumin on neuronal oxidative stress in the presence of Cu(II). Food Chem Toxicol, 2011
  150. Antioxidant and vascular protective effects of curcumin and tetrahydrocurcumin in rats with L-NAME-induced hypertension. Naunyn Schmiedebergs Arch Pharmacol, 2011
  151. Curcumin reverses corticosterone-induced depressive-like behavior and decrease in brain BDNF levels in rats. Neurosci Lett, 2011
  152. Potent anti-inflammatory effects of systemically administered curcumin modulate periodontal disease in vivo. J Periodontal Res, 2011
  153. Reversal of cardiac iron loading and dysfunction in thalassemic mice by curcuminoids. Med Chem, 2011
  154. Immunological studies on Amaranth, Sunset Yellow and Curcumin as food colouring agents in albino rats. Food Chem Toxicol, 2010
  155. Curcumin produces neuroprotective effects via activating brain-derived neurotrophic factor/TrkB-dependent MAPK and PI-3K cascades in rodent cortical neurons. Prog Neuropsychopharmacol Biol Psychiatry, 2010
  156. Curcumin reverses impaired cognition and neuronal plasticity induced by chronic stress. Neuropharmacology, 2009
  157. Antidepressant-like effects of curcumin on serotonergic receptor-coupled AC-cAMP pathway in chronic unpredictable mild stress of rats. Prog Neuropsychopharmacol Biol Psychiatry, 2009
  158. Curcumin protects PC12 cells from corticosterone-induced cytotoxicity: possible involvement of the ERK1/2 pathway. Basic Clin Pharmacol Toxicol, 2009
  159. Anti-depressant like effect of curcumin and its combination with piperine in unpredictable chronic stress-induced behavioral, biochemical and neurochemical changes. Pharmacol Biochem Behav, 2009
  160. [Preliminary study on molecular mechanism of curcumine anti-mouse melanoma]. Zhong Yao Cai, 2008
  161. Antidepressant activity of curcumin: involvement of serotonin and dopamine system. Psychopharmacology (Berl), 2008
  162. [Effect of curcumin on the expression of collagen type I protein and transforming growth factor-beta1 mRNA in pulmonary fibrosis rats]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi, 2008
  163. Curcumin protects against glutamate excitotoxicity in rat cerebral cortical neurons by increasing brain-derived neurotrophic factor level and activating TrkB. Brain Res, 2008
  164. The antidepressant effects of curcumin in the forced swimming test involve 5-HT1 and 5-HT2 receptors. Eur J Pharmacol, 2008
  165. Curcumin attenuates diabetic encephalopathy in rats: behavioral and biochemical evidences. Eur J Pharmacol, 2007
  166. Curcumin reverses impaired hippocampal neurogenesis and increases serotonin receptor 1A mRNA and brain-derived neurotrophic factor expression in chronically stressed rats. Brain Res, 2007
  167. Antioxidant potential of fluoxetine in comparison to Curcuma longa in restraint-stressed rats. Eur J Pharmacol, 2007
  168. Behavioral, neurochemical and neuroendocrine effects of the ethanolic extract from Curcuma longa L. in the mouse forced swimming test. J Ethnopharmacol, 2007
  169. Curcumin reverses the effects of chronic stress on behavior, the HPA axis, BDNF expression and phosphorylation of CREB. Brain Res, 2006
  170. Ethanolic extracts from Curcuma longa attenuates behavioral, immune, and neuroendocrine alterations in a rat chronic mild stress model. Biol Pharm Bull, 2006
  171. Amelioration of immune cell number depletion and potentiation of depressed detoxification system of tumor-bearing mice by curcumin. Cancer Detect Prev, 2005
  172. Antidepressant effects of curcumin in the forced swim test and olfactory bulbectomy models of depression in rats. Pharmacol Biochem Behav, 2005
  173. The effects of curcumin on depressive-like behaviors in mice. Eur J Pharmacol, 2005
  174. Protective effects of Curcuma longa on ischemia-reperfusion induced myocardial injuries and their mechanisms. Life Sci, 2004
  175. Antidepressant activity of aqueous extracts of Curcuma longa in mice. J Ethnopharmacol, 2002
  176. Phenolics: blocking agents for heterocyclic amine-induced carcinogenesis. Food Chem Toxicol, 1999
  177. Chemoprevention of heterocyclic amine-induced carcinogenesis by phenolic compounds in rats. Cancer Lett, 1999
  178. Antinociceptive and antidepressant-like profiles of BL-2401, a novel enkephalinase inhibitor, in mice and rats. Jpn J Pharmacol, 1997
  179. Inhibition of 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary tumorigenesis and DMBA-DNA adduct formation by curcumin. Cancer Lett, 1996
  180. Effect of arecoline on the curcumin-modulated hepatic biotransformation system enzymes in lactating mice and translactationally exposed F1 pups. Nutr Cancer, 1996
  181. Some aspects of pharmacological profile of sodium curcuminate. Indian J Physiol Pharmacol, 1984
Lab studies 95
  1. Effects of curcumin on depression, anxiety, and stress symptoms in adults: a GRADE-assessed systematic review and dose-response meta-analysis. Food Nutr Res, 2026
  2. Potential Adjunctive Effects of Quercetin-Curcumin Co-Supplementation in Adults with Mild-to-Moderate Long COVID: Results from a Pragmatic Exploratory Real-World Clinical Study. Pharmaceuticals (Basel), 2026
  3. Selective Anti-Inflammatory Actions of Curcumin on Cytokine Pathways in Major Depressive Disorder. Brain Behav, 2026
  4. Neuroimmune mechanisms of the gut-brain axis in treatment-resistant depression: Implications for microbiome-based therapeutic strategies. J Neuroimmunol, 2026
  5. Next-generation precision medicine for mood disorders: reproducible blood biomarkers enable objective diagnostics, subtyping, and targeted therapeutics. Mol Psychiatry, 2026
  6. A Review on the Mechanisms of Neurodegeneration and the Potential of Plant Bioactives in Managing Neurological Conditions. Curr Aging Sci, 2026
  7. Advances in Nano-Emulsion Intranasal Delivery Systems for Neurotherapeutics like Depression. Drug Metab Bioanal, 2026
  8. Curcumin alleviates depression-aggravated psoriasis by targeting MMP9-regulated apoptotic pathways. iScience, 2026
  9. Anti-Inflammatory Properties of Curcumin as Add-On Therapy in Patients with MS-Prospective, Comparative, Randomized, Pilot Study. Pharmaceutics, 2026
  10. p300/Ahnak1 promotes the depression of ICa,L of atrial myocytes induced by aging. Biochim Biophys Acta Mol Basis Dis, 2026
  11. The Effect of Curcumin Plus Piperine on Mental Health Status, Sleep Quality, and Anthropometric Indices in Patients with Non-Proliferative Diabetic Retinopathy: A Randomized Double-Blind Placebo-Controlled Trial. Int J Prev Med, 2026
  12. From spice to spotlight: Turmeric's safety concerns and the need for herbal education and enhanced regulation. J Am Pharm Assoc (2003), 2026
  13. Curcumin reprograms metabolic pathways and MAPK signaling to exert antidepressant effects. Biochem Biophys Rep, 2026
  14. Assessment of the Reporting Quality of Randomized Controlled Trials That Investigate the Efficacy of Curcumin for Treating Depression. Am J Ther, 2026
  15. Drug-Induced Liver Injury Associated With Turmeric and Black Pepper Based Dietary Supplements Consumption: A Case Report. Clin Case Rep, 2025
  16. Effect of curcumin on fatigue and musculoskeletal health in postmenopausal women: a double-blind randomised controlled trial. BMJ Open, 2025
  17. Phytotherapy and the Role of Bioactive Compounds in Modulating Mechanisms of Overweight and Obesity Comorbid with Depressive Symptoms-A Scoping Review of Mechanisms of Action. Molecules, 2025
  18. Decreased Systemic Monocyte Colony Protein-1 (MCP-1) Levels and Reduced sCD14 Levels in Curcumin-Treated Patients with Moderate Anxiety: A Pilot Study. Antioxidants (Basel), 2024
  19. The effect of curcumax on postpartum women's depression: a randomized controlled trial. Front Psychiatry, 2024
  20. One-step synthesis of amphiphilic copolymers PDMS-b-PEG using tris(pentafluorophenyl)borane and subsequent study of encapsulation and release of curcumin. J Mater Chem B, 2024
  21. Correction to "Efficacy and safety of curcumin in major depressive disorder: A randomized controlled trial". Phytother Res, 2024
  22. Understanding fenpropathrin-induced pulmonary toxicity: What apoptosis, inflammation, and pyreptosis reveal analyzing cross-links at the molecular, immunohistochemical, and immunofluorescent levels. Food Chem Toxicol, 2024
  23. Effect of Curcumin on Dysmenorrhea and Symptoms of Premenstrual Syndrome: A Systematic Review and Meta-Analysis. Korean J Fam Med, 2024
  24. Nano-curcumin effects on nicotine dependence, depression, anxiety and metabolic parameters in smokers: A randomized double-blind clinical study. Heliyon, 2023
  25. Exploration of Molecular Targets and Mechanisms of Curcumin in the Treatment of COVID-19 with Depression by an Integrative Pharmacology Strategy. Curr Pharm Des, 2023
  26. Various Extraction Techniques of Curcumin-A Comprehensive Review. ACS Omega, 2023
  27. Potential Antibacterial Activity of Ethanolic Curcuma longa L. Rhizome Extract Against Antibiotic-Resistant Bacteria. Pak J Biol Sci, 2023
  28. The Effect of Adding Curcumin to Sertraline in the Treatment of Severe Major Depressive Disorder: A Randomized, Double-Blind Clinical Trial. Clin Neuropharmacol, 2023
  29. Curcumin ameliorates chronic Toxoplasma gondii infection-induced affective disorders through modulation of proinflammatory cytokines and oxidative stress. Iran J Basic Med Sci, 2023
  30. Supercritical CO2 versus water as an antisolvent in the crystallization process to enhance dissolution rate of curcumin. Pharm Dev Technol, 2022
  31. Investigation of Antistress and Antidepressant Activities of Synthetic Curcumin Analogues: Behavioral and Biomarker Approach. Biomedicines, 2022
  32. The protective effects of curcumin on depression: Genes, transcription factors, and microRNAs involved. J Affect Disord, 2022
  33. Role of Inflammation, Oxidative Stress, and Mitochondrial Changes in Premenstrual Psychosomatic Behavioral Symptoms with Anti-Inflammatory, Antioxidant Herbs, and Nutritional Supplements. Oxid Med Cell Longev, 2022
  34. [Social jetlag: possibilities of micronutrient support]. Vopr Pitan, 2022
  35. Clinical Efficacy of Curcumin and Vitamin E on Inflammatory-Oxidative Stress Biomarkers and Primary Symptoms of Menopause in Healthy Postmenopausal Women: A Triple-Blind Randomized Controlled Trial. J Nutr Metab, 2022
  36. Curcumin Alleviates DSS-Induced Anxiety-Like Behaviors via the Microbial-Brain-Gut Axis. Oxid Med Cell Longev, 2022
  37. Natural Antioxidant Extracted Waste Cooking Oil as Sustainable Biolubricant Formulation in Tribological and Rheological Applications. Waste Biomass Valorization, 2022
  38. Honokiol combined with curcumin sensitizes multidrug-resistant human lung adenocarcinoma A549/DDP cells to cisplatin. Exp Ther Med, 2021
  39. Curcumin Reverses NNMT-Induced 5-Fluorouracil Resistance via Increasing ROS and Cell Cycle Arrest in Colorectal Cancer Cells. Biomolecules, 2021
  40. Evaluation of Effect of Curcumin on Psychological State of Patients with Pulmonary Hypertension by Magnetic Resonance Image under Deep Learning. Contrast Media Mol Imaging, 2021
  41. Turmeric and Curcumin: From Traditional to Modern Medicine. Adv Exp Med Biol, 2021
  42. Corrigendum to "The efficacy and acceptability of curcumin for the treatment of depression or depressive symptoms: A systematic review and meta-analysis". [Journal of Affective Disorders 282 (2021) 242-251]. J Affect Disord, 2021
  43. Investigating crystallization tendency, miscibility, and molecular interactions of drug-polymer systems for the development of amorphous solid dispersions. Drug Dev Ind Pharm, 2021
  44. Creation of a gene expression portrait of depression and its application for identifying potential treatments. Sci Rep, 2021
  45. Iron overload adversely effects bone marrow haematogenesis via SIRT-SOD2-mROS in a process ameliorated by curcumin. Cell Mol Biol Lett, 2021
  46. Protective effects of curcumin towards anxiety and depression-like behaviors induced mercury chloride. Saudi J Biol Sci, 2021
  47. Solid lipid nanoparticles loading with curcumin and dexanabinol to treat major depressive disorder. Neural Regen Res, 2021
  48. Effects of Turmeric on Cardiovascular Risk Factors, Mental Health, and Serum Homocysteine in Overweight, Obese Females. Altern Ther Health Med, 2021
  49. Fight COVID-19 depression with immunity booster: Curcumin for psychoneuroimmunomodulation. Asian J Psychiatr, 2020
  50. Sub-Acute Treatment of Curcumin Derivative J147 Ameliorates Depression-Like Behavior Through 5-HT1A-Mediated cAMP Signaling. Front Neurosci, 2020
  51. [Curcumin as an ajuvant treatment of depression: mechanisms of action and application prospects]. Zh Nevrol Psikhiatr Im S S Korsakova, 2020
  52. Curcumin attenuates copper-induced oxidative stress and neurotoxicity in Drosophila melanogaster. Toxicol Rep, 2020
  53. The Preparation of Curcumin Sustained-Release Solid Dispersion by Hot Melt Extrusion-Ⅰ. Optimization of the Formulation. J Pharm Sci, 2020
  54. Temperature Evaluation of Curcumin Keto-Enolic Kinetics and Its Interaction with Two Pluronic Copolymers. J Phys Chem B, 2019
  55. The inhibitory role of curcumin derivatives on AMPA receptor subunits and their effect on the gating biophysical properties. Eur J Pharm Sci, 2019
  56. Nutraceuticals to promote neuronal plasticity in response to corticosterone-induced stress in human neuroblastoma cells. Nutr Neurosci, 2019
  57. Curcumin suppresses gastric cancer biological activity by regulation of miRNA-21: an in vitro study. Int J Clin Exp Pathol, 2018
  58. Dietary Variations in a Multiethnic Parkinson's Disease Cohort and Possible Influences on Nonmotor Aspects: A Cross-Sectional Multicentre Study. Parkinsons Dis, 2018
  59. Synergistic delivery of 5-fluorouracil and curcumin using human serum albumin-coated iron oxide nanoparticles by folic acid targeting. Prog Biomater, 2018
  60. The Effects of Curcumae Longae Radix, Curcuma phaeocaulis Radix and Their Processed Products on Epo/EpoR Pathway and CD62p. Front Pharmacol, 2018
  61. Development of antioxidant gliadin particle stabilized Pickering high internal phase emulsions (HIPEs) as oral delivery systems and the in vitro digestion fate. Food Funct, 2018
  62. Immunomodulatory effects of phytogenics in chickens and pigs - A review. Asian-Australas J Anim Sci, 2018
  63. Curcumin/sunitinib co-loaded BSA-stabilized SPIOs for synergistic combination therapy for breast cancer. J Mater Chem B, 2017
  64. Curcumin-coordinated nanoparticles with improved stability for reactive oxygen species-responsive drug delivery in lung cancer therapy. Int J Nanomedicine, 2017
  65. Single cell amperometry reveals curcuminoids modulate the release of neurotransmitters during exocytosis from PC12 cells. J Electroanal Chem (Lausanne), 2016
  66. Curcumin inhibits invasive capabilities through epithelial mesenchymal transition in breast cancer cell lines. Int J Oncol, 2016
  67. In vitro assessment of the combined effect of eicosapentaenoic acid, green tea extract and curcumin C3 on protein loss in C2C12 myotubes. In Vitro Cell Dev Biol Anim, 2016
  68. Curcumin Protects Neurons from Glutamate-Induced Excitotoxicity by Membrane Anchored AKAP79-PKA Interaction Network. Evid Based Complement Alternat Med, 2015
  69. Thermo-responsive drug release from self-assembled micelles of brush-like PLA/PEG analogues block copolymers. Int J Pharm, 2015
  70. Protection of curcumin against amyloid-β-induced cell damage and death involves the prevention from NMDA receptor-mediated intracellular Ca2+ elevation. J Recept Signal Transduct Res, 2015
  71. Investigation and correlation of drug polymer miscibility and molecular interactions by various approaches for the preparation of amorphous solid dispersions. Eur J Pharm Sci, 2015
  72. A critical examination of studies on curcumin for depression. J Clin Psychiatry, 2014
  73. Does Curcumin or Pindolol Potentiate Fluoxetine's Antidepressant Effect by a Pharmacokinetic or Pharmacodynamic Interaction? Indian J Pharm Sci, 2014
  74. Curcumin attenuates amyloid-β-induced tau hyperphosphorylation in human neuroblastoma SH-SY5Y cells involving PTEN/Akt/GSK-3β signaling pathway. J Recept Signal Transduct Res, 2014
  75. Mechanisms underlying the beneficial effects of Kaiyu Granule for depression. Neural Regen Res, 2013
  76. Curcumin and anthocyanin inhibit pepsin-mediated cell damage and carcinogenic changes in airway epithelial cells. Ann Otol Rhinol Laryngol, 2013
  77. Curcumin as an add-on to antidepressive treatment. Clin Neuropharmacol, 2013
  78. Yoga for back pain, cranberry for cystitis prevention, soy isoflavones for hot flashes, curcumin for pre-diabetes, and breathing retraining for asthma. Explore (NY), 2013
  79. Down-regulation of thymic stromal lymphopoietin by curcumin. Pharmacol Rep, 2013
  80. Natural inhibitors of indoleamine 3,5-dioxygenase induced by interferon-gamma in human neural stem cells. Biochem Biophys Res Commun, 2012
  81. Curcumin blocks small cell lung cancer cells migration, invasion, angiogenesis, cell cycle and neoplasia through Janus kinase-STAT3 signalling pathway. PLoS One, 2012
  82. Effect of curcumin on liposome: curcumin as a molecular probe for monitoring interaction of ionic liquids with 1,2-dipalmitoyl-sn-glycero-3-phosphocholine liposome. Photochem Photobiol, 2012
  83. The curcumin analogue hydrazinocurcumin exhibits potent suppressive activity on carcinogenicity of breast cancer cells via STAT3 inhibition. Int J Oncol, 2012
  84. Mango ginger (Curcuma amada Roxb.)--a promising spice for phytochemicals and biological activities. J Biosci, 2011
  85. Fluoxetine attenuates the inhibitory effect of glucocorticoid hormones on neurogenesis in vitro via a two-pore domain potassium channel, TREK-1. Psychopharmacology (Berl), 2011
  86. An overview of curcumin in neurological disorders. Indian J Pharm Sci, 2010
  87. Oxidative stress modulates PPAR gamma in vascular endothelial cells. Free Radic Biol Med, 2010
  88. Biological effects of some natural and chemical compounds on the potato tuber moth, Phthorimaea operculella Zell. (Lepidoptera:Gelechiidae). Saudi J Biol Sci, 2009
  89. Curcumin, both histone deacetylase and p300/CBP-specific inhibitor, represses the activity of nuclear factor kappa B and Notch 1 in Raji cells. Basic Clin Pharmacol Toxicol, 2007
  90. Not in the mind of neurasthenic lazybones but in the cell nucleus: patients with chronic fatigue syndrome have increased production of nuclear factor kappa beta. Neuro Endocrinol Lett, 2007
  91. Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer's disease patients are improved by bisdemethoxycurcumin. Proc Natl Acad Sci U S A, 2007
  92. Antioxidative effects of plant polyphenols: from protection of G protein signaling to prevention of age-related pathologies. Ann N Y Acad Sci, 2007
  93. [Inhibitory effect of curcumin on angiogenesis induced by brain derived neurotrophic factor from multiple myeloma cells]. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2006
  94. Signal pathways underlying homocysteine-induced production of MCP-1 and IL-8 in cultured human whole blood. Acta Pharmacol Sin, 2005
  95. Curcumin inhibits cell proliferation by interfering with the cell cycle and inducing apoptosis in colon carcinoma cells. Anticancer Res, 1999
Reviews 131
  1. Curcumin as a Potential Therapy for Postoperative Pain: A Systematic Review. J Integr Complement Med, 2026
  2. (Poly)phenol intake and mental health: a scoping review. Crit Rev Food Sci Nutr, 2026
  3. Brain-Gut Axis Perspective on Irritable Bowel Syndrome: The Role of Gut Microbiota and Therapeutic Strategies of Traditional Chinese Medicine. Am J Chin Med, 2026
  4. Plant-derived bioactives and nanotechnology-enabled delivery in diabetic neuropathy: molecular mechanisms, therapeutic advances, and translational perspectives. J Drug Target, 2026
  5. Research progress on chemical composition, pharmacological effects, clinical applications, and processing of Curcumae Radix. Front Pharmacol, 2026
  6. Efficacy of curcumin in depression: A grade-assessed systematic review and meta-analysis of randomized controlled trials. Ann Gen Psychiatry, 2026
  7. Ayurvedic Dravya-Based Herbal Products for Cognition, Stress, Sleep, and Psychiatric Symptoms: A Node-Resolved Systematic Review and Meta-Analysis. J Integr Complement Med, 2026
  8. Exploring the potential of polyphenols in major depression: from molecular function to clinical therapy. Front Nutr, 2026
  9. Efficacy and Safety of Herbal Supplements with Anxiolytic, Antidepressant, and Sedative Action: A Review of Clinical Data and Toxicological Risks. Pharmaceuticals (Basel), 2026
  10. Molecular pathways of Traditional Chinese medicine-derived compounds in cognitive decline and depressive disorders: Neuroinflammation, synaptic plasticity and stress axis regulation. Pak J Pharm Sci, 2026
  11. Targeting the mTOR Pathway with Natural Products: A Potential Therapeutic Approach for Autism Spectrum Disorders. Curr Neuropharmacol, 2026
  12. Mood food: antidepressant effects of culinary spices. Front Nutr, 2026
  13. Curcumin as a Multi-Target Bioactive Molecule: Mechanistic Insights and Translational Perspectives. Int J Mol Sci, 2026
  14. The Analgesic Effects of Nrf2 Activators in Chemotherapy-Induced Neuropathic Pain: Evidence from Animal Studies and Consequences for Translation into Clinical Trials. Int J Mol Sci, 2026
  15. Medicinal Plants for Major Depressive Disorder. Brain Sci, 2026
  16. Neurotherapeutic promise of egg-derived antioxidants: mental health implications, and future perspectives. J Sci Food Agric, 2026
  17. Curcumin, an anti-inflammatory drug: a key player in treating depression. Nat Prod Res, 2026
  18. Plant-Derived Nutraceuticals in Mental Health and Brain Function: Mechanisms of Action and Therapeutic Potential. Int J Mol Sci, 2025
  19. Unlocking Mysteries: Exploring the Dynamic Interplay Among Sleep, the Immune System, and Curcumin in Contemporary Research. Sleep Sci, 2025
  20. Modulating nuclear factor erythroid 2-related factor 2 and heme oxygenase-1 in liver-brain axis disorders. World J Psychiatry, 2025
  21. A perspective on the chemical structures and molecular mechanisms of curcumin and its derivatives and analogs in cancer treatment (Review). Int J Oncol, 2025
  22. A Scoping Narrative Review of Curcumin in Pain Medicine: The Need for Further Study. Integr Med (Encinitas), 2025
  23. Peripheral Immune-Inflammatory Pathways in Major Depressive Disorder, Bipolar Disorder, and Schizophrenia: Exploring Their Potential as Treatment Targets. CNS Drugs, 2025
  24. Phytochemicals encouraging neurotrophic pathways: brain-derived neurotrophic factors as molecular targets in depression. Naunyn Schmiedebergs Arch Pharmacol, 2025
  25. Neuroinflammation and Natural Antidepressants: Balancing Fire with Flora. Biomedicines, 2025
  26. Novel Insights into Dietary Bioactive Compounds and Major Depressive Disorders: Evidence from Animal Studies and Future Perspectives. J Nutr, 2025
  27. A comprehensive review on the impact of polyphenol supplementation and exercise on depression and brain function parameters. Behav Brain Funct, 2025
  28. Fluoride-induced Neurodevelopmental Toxicity- AMPK as a Possible Target. CNS Neurol Disord Drug Targets, 2025
  29. The Dynamic Role of Curcumin in Mitigating Human Illnesses: Recent Advances in Therapeutic Applications. Pharmaceuticals (Basel), 2024
  30. Plants with Potential Importance in Supporting the Treatment of Depression: Current Trends, and Research. Pharmaceuticals (Basel), 2024
  31. Functional Food Nutrients, Redox Resilience Signaling and Neurosteroids for Brain Health. Int J Mol Sci, 2024
  32. Noise exposure-induced the cerebral alterations: From emerging evidence to antioxidant-mediated prevention and treatment. Ecotoxicol Environ Saf, 2024
  33. Advances of curcumin in nervous system diseases: the effect of regulating oxidative stress and clinical studies. Front Pharmacol, 2024
  34. Curcumin and nano-curcumin applications in psychiatric disorders. Phytother Res, 2024
  35. Is Curcumin Intake Really Effective for Chronic Inflammatory Metabolic Disease? A Review of Meta-Analyses of Randomized Controlled Trials. Nutrients, 2024
  36. Curcumin as a Multifunctional Spice Ingredient against Mental Disorders in Humans: Current Clinical Studies and Bioavailability Concerns. Life (Basel), 2024
  37. Curcumae Radix: A Review of Traditional Use, Phytochemistry, Pharmacology, Toxicology and Quality Control. Chem Biodivers, 2024
  38. Targeted therapies of curcumin focus on its therapeutic benefits in cancers and human health: Molecular signaling pathway-based approaches and future perspectives. Biomed Pharmacother, 2024
  39. Curcumin Derivatives Linked to a Reduction of Oxidative Stress in Mental Dysfunctions and Inflammatory Disorders. Curr Med Chem, 2024
  40. The Effects of Curcumin on Brain-Derived Neurotrophic Factor Expression in Neurodegenerative Disorders. Curr Med Chem, 2024
  41. Current status of Complementary and Alternative Medicine Interventions in the Management of Pancreatic Cancer - An Overview. Curr Treat Options Oncol, 2023
  42. Current evidence for J147 as a potential therapeutic agent in nervous system disease: a narrative review. BMC Neurol, 2023
  43. From Plants to Psycho-Neurology: Unravelling the Therapeutic Benefits of Bioactive Compounds in Brain Disorders. Antioxidants (Basel), 2023
  44. The Role of Gut Microbiota in Anxiety, Depression, and Other Mental Disorders as Well as the Protective Effects of Dietary Components. Nutrients, 2023
  45. Recent advances in curcumin-based nanoformulations in diabetes. J Drug Target, 2023
  46. [Complementary methods in the treatment of complex regional pain syndrome]. Schmerz, 2023
  47. Curcumin: Overview of Extraction Methods, Health Benefits, and Encapsulation and Delivery Using Microemulsions and Nanoemulsions. Int J Mol Sci, 2023
  48. Therapeutic Implications of Some Natural Products for Neuroimmune Diseases: A Narrative of Clinical Studies Review. Evid Based Complement Alternat Med, 2023
  49. Potential of Nano-Antioxidants and Nanomedicine for Recovery from Neurological Disorders Linked to Long COVID Syndrome. Antioxidants (Basel), 2023
  50. Complementary and Integrative Medicine in Pancreatic Cancer. Curr Oncol Rep, 2023
  51. Curcumin-piperine co-supplementation and human health: A comprehensive review of preclinical and clinical studies. Phytother Res, 2023
  52. Effect of nano-curcumin on various diseases: A comprehensive review of clinical trials. Biofactors, 2023
  53. The Dialogue Between Neuroinflammation and Adult Neurogenesis: Mechanisms Involved and Alterations in Neurological Diseases. Mol Neurobiol, 2023
  54. Therapeutic role of curcumin in adult neurogenesis for management of psychiatric and neurological disorders: a scientometric study to an in-depth review. Crit Rev Food Sci Nutr, 2023
  55. Curcumae Rhizoma: A botanical drug against infectious diseases. Front Pharmacol, 2022
  56. Mechanistic insights into the role of plant polyphenols and their nano-formulations in the management of depression. Front Pharmacol, 2022
  57. An Overview of Parkinson's Disease: Curcumin as a Possible Alternative Treatment. Cureus, 2022
  58. [Research progress of Curcuma kwangsiensis root tubers and analysis of liver protection and anti-tumor mechanisms based on Q-markers]. Zhongguo Zhong Yao Za Zhi, 2022
  59. A Comprehensive Review on the Therapeutic Potential of Curcuma longa Linn. in Relation to its Major Active Constituent Curcumin. Front Pharmacol, 2022
  60. An Update on the Exploratory Use of Curcumin in Neuropsychiatric Disorders. Antioxidants (Basel), 2022
  61. Potential Role of Curcumin for the Treatment of Major Depressive Disorder. CNS Drugs, 2022
  62. Novel Drug Delivery System for Curcumin: Implementation to Improve Therapeutic Efficacy against Neurological Disorders. Comb Chem High Throughput Screen, 2022
  63. Medicinal Plants in the Treatment of Depression. II: Evidence from Clinical Trials. Planta Med, 2022
  64. Anti-Inflammatory Effects of Curcumin in the Inflammatory Diseases: Status, Limitations and Countermeasures. Drug Des Devel Ther, 2021
  65. Regulatory roles of phytochemicals on circular RNAs in cancer and other chronic diseases. Pharmacol Res, 2021
  66. Chronic Stress and Oxidative Stress as Common Factors of the Pathogenesis of Depression and Alzheimer's Disease: The Role of Antioxidants in Prevention and Treatment. Antioxidants (Basel), 2021
  67. Therapeutic approaches employing natural compounds and derivatives for treating bipolar disorder: emphasis on experimental models of the manic phase. Metab Brain Dis, 2021
  68. Nutritional Supplements for the Treatment of Neuropathic Pain. Biomedicines, 2021
  69. Advances in Alternative and Integrative Medicine in the Treatment of Depression: A Review of the Evidence. Arch Iran Med, 2021
  70. Some Candidate Drugs for Pharmacotherapy of Alzheimer's Disease. Pharmaceuticals (Basel), 2021
  71. Effects of Curcumin and Its Different Formulations in Preclinical and Clinical Studies of Peripheral Neuropathic and Postoperative Pain: A Comprehensive Review. Int J Mol Sci, 2021
  72. Plant-based Medicines (Phytoceuticals) in the Treatment of Psychiatric Disorders: A Meta-review of Meta-analyses of Randomized Controlled Trials: Les médicaments à base de plantes (phytoceutiques) dans le traitement des troubles psychiatriques: une méta-revue des méta-analyses d'essais randomisés contrôlés. Can J Psychiatry, 2021
  73. Medicinal Plants in the Treatment of Depression: Evidence from Preclinical Studies. Planta Med, 2021
  74. Gulf War Illness: Mechanisms Underlying Brain Dysfunction and Promising Therapeutic Strategies. Pharmacol Ther, 2021
  75. Curcumin in Depression: Potential Mechanisms of Action and Current Evidence-A Narrative Review. Front Psychiatry, 2020
  76. Indian Medicinal Herbs and Formulations for Alzheimer's Disease, from Traditional Knowledge to Scientific Assessment. Brain Sci, 2020
  77. Curcumin: Could This Compound Be Useful in Pregnancy and Pregnancy-Related Complications? Nutrients, 2020
  78. The Emerging Role of Nutraceuticals and Phytochemicals in the Prevention and Treatment of Alzheimer's Disease. J Alzheimers Dis, 2020
  79. Curcumin in antidepressant treatments: An overview of potential mechanisms, pre-clinical/clinical trials and ongoing challenges. Basic Clin Pharmacol Toxicol, 2020
  80. Therapeutic potential of glutathione-enhancers in stress-related psychopathologies. Neurosci Biobehav Rev, 2020
  81. Highly Bioavailable Forms of Curcumin and Promising Avenues for Curcumin-Based Research and Application: A Review. Molecules, 2020
  82. Role of curcumin and its nanoformulations in neurotherapeutics: A comprehensive review. J Biochem Mol Toxicol, 2020
  83. New Development of Novel Berberine Derivatives against Bacteria. Mini Rev Med Chem, 2020
  84. Turmeric supplements. Med Lett Drugs Ther, 2019
  85. Complementary therapies for clinical depression: an overview of systematic reviews. BMJ Open, 2019
  86. Benefits of curcumin in brain disorders. Biofactors, 2019
  87. Neuroprotective potency of some spice herbs, a literature review. J Tradit Complement Med, 2019
  88. Investigation of the utility of Curcuma caesia in the treatment of diabetic neuropathy. J Pharm Pharmacol, 2019
  89. Advances in curcumin-loaded nanopreparations: improving bioavailability and overcoming inherent drawbacks. J Drug Target, 2019
  90. Curcumin as a therapeutic agent in leukemia. J Cell Physiol, 2019
  91. Natural health products, dietary minerals and over-the-counter medications as add-on therapies to antidepressants in the treatment of major depressive disorder: a review. Brain Res Bull, 2019
  92. Biological clocks, some clock-related diseases, and medicinal plants. Psych J, 2018
  93. Role of curcumin in the management of pathological pain. Phytomedicine, 2018
  94. The clinical efficacy of curcumin-containing nutraceuticals: An overview of systematic reviews. Pharmacol Res, 2018
  95. Inducers of Senescence, Toxic Compounds, and Senolytics: The Multiple Faces of Nrf2-Activating Phytochemicals in Cancer Adjuvant Therapy. Mediators Inflamm, 2018
  96. Curcumin-mediated regulation of intestinal barrier function: The mechanism underlying its beneficial effects. Tissue Barriers, 2018
  97. Pharmacokinetic interactions of curcuminoids with conventional drugs: A review. J Ethnopharmacol, 2017
  98. The olfactory bulbectomized rat as a model of depression: The hippocampal pathway. Behav Brain Res, 2017
  99. Curcumin, an active component of turmeric (Curcuma longa), and its effects on health. Crit Rev Food Sci Nutr, 2017
  100. Berberine and Its Role in Chronic Disease. Adv Exp Med Biol, 2016
  101. Incorporating Natural Products, Pharmaceutical Drugs, Self-Care and Digital/Mobile Health Technologies into Molecular-Behavioral Combination Therapies for Chronic Diseases. Curr Clin Pharmacol, 2016
  102. Curcumin in depressive disorders: An overview of potential mechanisms, preclinical and clinical findings. Eur J Pharmacol, 2016
  103. Cognitive remission: a novel objective for the treatment of major depression? BMC Med, 2016
  104. An appraisal on recent medicinal perspective of curcumin degradant: Dehydrozingerone (DZG). Bioorg Med Chem, 2016
  105. Inflammation and Immune Regulation as Potential Drug Targets in Antidepressant Treatment. Curr Neuropharmacol, 2016
  106. Recent developments in curcumin and curcumin based polymeric materials for biomedical applications: A review. Int J Biol Macromol, 2015
  107. Psychiatric Disorders and Polyphenols: Can They Be Helpful in Therapy? Oxid Med Cell Longev, 2015
  108. Synthetic and natural inhibitors of phospholipases A2: their importance for understanding and treatment of neurological disorders. ACS Chem Neurosci, 2015
  109. Plant-derived natural medicines for the management of depression: an overview of mechanisms of action. Rev Neurosci, 2015
  110. Curcumin as a putative antidepressant. Expert Rev Neurother, 2015
  111. Relevance of the anti-inflammatory properties of curcumin in neurodegenerative diseases and depression. Molecules, 2014
  112. Protective activity of medicinal plants and their isolated compounds against the toxic effects from the venom of Naja (cobra) species. J Ethnopharmacol, 2014
  113. [Long-term complications of sulfur mustard exposure: a therapeutic update]. Harefuah, 2014
  114. The glutathione system: a new drug target in neuroimmune disorders. Mol Neurobiol, 2014
  115. Inflamed moods: a review of the interactions between inflammation and mood disorders. Prog Neuropsychopharmacol Biol Psychiatry, 2014
  116. Oxidative/nitrosative stress and immuno-inflammatory pathways in depression: treatment implications. Curr Pharm Des, 2014
  117. Herbal therapeutics that block the oncogenic kinase PAK1: a practical approach towards PAK1-dependent diseases and longevity. Phytother Res, 2014
  118. Curcumin: a novel therapeutic for burn pain and wound healing. Expert Opin Investig Drugs, 2013
  119. Curcumin-free turmeric exhibits anti-inflammatory and anticancer activities: Identification of novel components of turmeric. Mol Nutr Food Res, 2013
  120. Natural polyphenols in the management of major depression. Expert Opin Investig Drugs, 2013
  121. Curcumin, an active constiuent of the ancient medicinal herb Curcuma longa L.: some uses and the establishment and biological basis of medical efficacy. CNS Neurol Disord Drug Targets, 2013
  122. Potential of treating age-related depression and cognitive decline with nutraceutical approaches: a mini-review. Gerontology, 2013
  123. Multitargeting by turmeric, the golden spice: From kitchen to clinic. Mol Nutr Food Res, 2013
  124. Multiple antidepressant potential modes of action of curcumin: a review of its anti-inflammatory, monoaminergic, antioxidant, immune-modulating and neuroprotective effects. J Psychopharmacol, 2012
  125. Antioxidants as antidepressants: fact or fiction? CNS Drugs, 2012
  126. Role of nuclear factor κB-mediated inflammatory pathways in cancer-related symptoms and their regulation by nutritional agents. Exp Biol Med (Maywood), 2011
  127. Potentials of curcumin as an antidepressant. ScientificWorldJournal, 2009
  128. Current investigational drugs for major depression. Expert Opin Investig Drugs, 2009
  129. Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem Pharmacol, 2008
  130. Herbal medication: potential for adverse interactions with analgesic drugs. J Clin Pharm Ther, 2002
  131. Herbals, cancer prevention and health. J Nutr, 2001
Other papers, not yet read by us 27
  1. Defined Natural Products as Adjunctive Therapies: Evidence-Gated Polypharmacology Across Molecular Targets, Human Exposure, Clinical Signals, and Safety Boundaries. Int J Mol Sci, 2026
  2. The NO-cGMP signaling pathway and depression: mechanisms and therapeutic prospects. Mol Biol Rep, 2026
  3. Pilot Trial of Adjunctive Curcumin for Treatment-Resistant Bipolar Depression in Youth: Focus on Inflammation and Oxidative Stress. J Child Adolesc Psychopharmacol, 2026
  4. A Randomized Controlled Trial to Determine the Effects of Curcumin and Epigallocatechin-3-Gallate Supplementation on Serum Brain-Derived Neurotrophic Factor and Mood Disturbance in Adults. Nutrients, 2026
  5. Synergistic Effects of Exercise and Nano-Curcumin Supplementation in Women with Lifestyle-Related Diseases: A Scoping Review. Nutrients, 2025
  6. Mental health and health-related quality of life response to curcumin-probiotic drink powder co-supplementation in adults with overweight/obesity and metabolic syndrome: a four-arm randomised, double-blind, placebo-controlled, clinical trial. Br J Nutr, 2025
  7. Relationship of Curcumin with Aging and Alzheimer and Parkinson Disease, the Most Prevalent Age-Related Neurodegenerative Diseases: A Narrative Review. Nutr Rev, 2025
  8. Phytochemicals in the treatment of patients with depression: a systemic review. Front Psychiatry, 2024
  9. Effect of nano-curcumin supplementation on cardiometabolic risk factors, physical and psychological quality of life, and depression in patients with coronary slow flow phenomenon: a randomized double-blind clinical trial. Trials, 2024
  10. Polyphenols Targeting NF-κB Pathway in Neurological Disorders: What We Know So Far? Int J Biol Sci, 2024
  11. Curcumin-rich curry consumption and life expectancy: Singapore longitudinal ageing study. Geroscience, 2024
  12. Nutraceuticals in mood disorders: current knowledge and future directions. Curr Opin Psychiatry, 2023
  13. Herbal Approaches in the Management of Mental Depression. CNS Neurol Disord Drug Targets, 2023
  14. Effects of Curcumin on Depression and Anxiety: A Narrative Review of the Recent Clinical Data. Adv Exp Med Biol, 2021
  15. A systematic review of the antidepressant effects of curcumin: Beyond monoamines theory. Aust N Z J Psychiatry, 2021
  16. An Exploratory Analysis of Changes in Mental Wellbeing Following Curcumin and Fish Oil Supplementation in Middle-Aged and Older Adults. Nutrients, 2020
  17. Antidepressant active ingredients from herbs and nutraceuticals used in TCM: pharmacological mechanisms and prospects for drug discovery. Pharmacol Res, 2019
  18. Novel targets for parkinsonism-depression comorbidity. Prog Mol Biol Transl Sci, 2019
  19. Putative neuroprotective pharmacotherapies to target the staged progression of mental illness. Early Interv Psychiatry, 2019
  20. Herbal medicines in the treatment of psychiatric disorders: 10-year updated review. Phytother Res, 2018
  21. Effects of curcumin consumption on human chronic diseases: A narrative review of the most recent clinical data. Phytother Res, 2018
  22. Curcumin for neuropsychiatric disorders: a review of in vitro, animal and human studies. J Psychopharmacol, 2017
  23. Duality of Antidepressants and Neuroprotectants. Neurotox Res, 2016
  24. The Role of Curcumin Administration in Patients with Major Depressive Disorder: Mini Meta-Analysis of Clinical Trials. Phytother Res, 2016
  25. Curcumin and major depression: a randomised, double-blind, placebo-controlled trial investigating the potential of peripheral biomarkers to predict treatment response and antidepressant mechanisms of change. Eur Neuropsychopharmacol, 2015
  26. Neuroinflammation, neurodegeneration, and depression. Neurotox Res, 2013
  27. Medicinal plants and dementia therapy: herbal hopes for brain aging? CNS Neurosci Ther, 2011

Other conditions Turmeric has been studied for

Checked against PubMed on 2026-10-28. Everything we know about Turmeric